Approaches for Dissection of the Genetic Basis of Complex Disease Development in Human by Nicole J. Lake et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
13 
Approaches for Dissection of  
the Genetic Basis of Complex 
 Disease Development in Humans 
Nicole J. Lake, Kiymet Bozaoglu,  
Abdul W. Khan and Jeremy B. M. Jowett 
Baker IDI Heart and Diabetes Institute, Melbourne, 
 Australia  
1. Introduction 
When genome-wide association (GWA) studies emerged as an approach for dissecting the 
genetic architecture of complex disease, there were great hopes for its potential to unlock the 
mysteries of complex human disease, a full dissection of which had largely evaded 
numerous genetic linkage analyses and candidate gene studies. Based on the hypothesis that 
common variants influenced much of common disease development, GWA focus was 
initially on common allelic variants with a minor allele frequency of at least 5%. Six years 
and thousands of these associated loci down the track, GWA studies have seemingly 
reached a fork in the road. It has become apparent that the influence of common variants on 
complex disease development can only explain a modest proportion of phenotypic 
variation. Furthermore difficulty in finding the causal variant for an associated locus has 
slowed anticipated translation towards the clinic. Consequently there has been wide 
discussion surrounding the limitations of GWA studies and value of a continued focus on 
common variants. A key debate therefore has arisen at this nexus that compares the 
Common Disease-Common Variant against the emerging Common Disease-Rare Variant 
hypothesis that is now gathering support.  
In this chapter we discuss whether further progress can be made with the GWA approach 
and contrast its potential against a future with increasingly affordable whole-genome 
sequencing. We also explore the various sequencing strategies that seek to make progress 
within tight research budgets. Success in elucidating the genetic architecture of complex 
human disease has the potential to affect many by laying the foundations for understanding 
the complex mechanisms of disease facilitating translation into new drug treatments and the 
development of biomarkers for assessment of onset of disease.  
2. Background 
Complex human diseases represent a serious global health concern. Development of 
complex common diseases including cardiovascular disease (CVD) and diabetes relies on an 
intricate network of interactions between genes and environment. The continuum over 
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which a complex disease can be defined is itself influenced by continuous traits such as CVD 
being influenced by weight and cholesterol levels. It is thus not unexpected that approaches 
to decode such complex genetic puzzles have been slow in their progress.  
GWA studies survey the association of single nucleotide polymorphisms (SNPs) with a disease 
or trait to identify genetic loci. Commercial chips use a ‘tag’ SNP for each region of linkage 
disequilibrium to capture variation across genomes by high-throughput genotyping 
technologies (Manolio et al. 2009; Witte 2010). The large numbers of samples that can be 
processed relatively inexpensively provides GWA study designs with excellent statistical 
power to detect modest effect sizes that have been integral to its success. The utility of GWA 
produced data has enabled efficient replication studies and consequent reduction of false-
positive findings. The advent of GWA was an important advance on the existing approaches 
used for dissecting human disease and the first approach tailored for complex disease 
research. Prior to this, linkage analysis used comparatively widely spaced polymorphic 
markers and determined their co-segregation with the disease or trait in affected families. 
While this proved effective for isolating rare, highly penetrant variants associated with 
Mendelian diseases, it struggled to provide disease gene identification due to broad 
localisation intervals. Additionally the variable heritability of many complex phenotypes and 
challenges in accurate trait measurement may have contributed to the shortcomings of those 
linkage studies (Hirschhorn et al. 2005). On the other hand, candidate gene studies offered 
higher resolution but ignored most of the genome. The reliance on a correct hypothesis for the 
candidate gene’s involvement in disease risk can also result in false-positive associations 
(Witte 2010) or true associations that were difficult to replicate (Manolio et al. 2009).   
The Common Disease-Common Variant (CDCV) hypothesis provided inspiration and 
optimism that GWA studies were a feasible approach for characterising the genetic 
architecture of complex common diseases. Largely brought to attention by Lander and Reich 
(Reich et al. 2001), the CDCV had some attractive qualities. The well established ‘Out of 
Africa’ model illustrated proliferation of the global population from a small group of 
founders, a dynamic which could have allowed mutations to become common (Iyengar et al. 
2007). CDCV supporters (Lander 1996; Collins et al. 1998) explained that these common 
variants that were once neutral, or even beneficial, had become harmful in the context of 
dramatic environmental changes (Kryukov et al. 2007). As the HapMap project progressed, 
efficiently characterising patterns of linkage disequilibrium, testing of the CDCV hypothesis 
became a possibility using the emerging platforms and GWA study design. Free from the 
constriction of a functional hypothesis and candidate gene focus, GWA studies have 
revealed numerous loci previously not implicated in complex disease and further allowed 
investigation of the genetic basis of commonality between multiple complex phenotypes 
(Frazer et al. 2009). However despite these successes, the validity of the CDCV hypothesis is 
under challenge (Frazer et al. 2009) and the translation of the findings to useful mechanistic 
knowledge has been problematic.  
3. Genome-Wide Association study designs 
A GWA study can be undertaken using several different designs. The traditional GWA 
study approach has been a case-control design, but cohort studies and family-based 
approaches also have merit. Each offers unique advantages and drawbacks. Cost, time and 
intentions for data application are key influences over the optimal choice of design.  
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3.1 Case-control  
Traditionally, disease associated loci were illustrated by comparison of population-based 
affected ‘case’ and unaffected ‘control’ groups. Control groups can be shared between 
studies without introducing bias (2007; Witte 2010). Case-control designs can thus be 
organised easily and at minimum costs for large group sizes. The ability to survey unrelated 
individuals is a strength of GWA studies for ease of ascertainment of study participants. 
However it also raises issues such as confounding effects of population stratification 
(Thomas et al. 2002; Wacholder et al. 2002) where the genotyped variants may have different 
frequencies among ethnically defined strata of a population. The differences in allele 
frequencies between these strata can create false-positive associations (Dickson et al. 2010). 
Initially there were significant concerns for the impact of population stratification on the 
GWA approach (Thomas et al. 2002), however recent findings (Wacholder et al. 2002; 2007; 
Goldstein 2009; Hindorff et al. 2009) have largely quelled this discussion by showing the 
confounding effects of stratification were overestimated. This is not to say however that it 
does not exist, but rather that careful consideration of population samples and genotyping 
of specific sets of variants can reduce bias and provide the ability to detect and adjust for it if 
present.  
3.2 Cohort  
Cohort design is distinct from case-control GWA study design where a sample of the 
population, the cohort, is randomly ascertained and traits relevant for the disease of interest 
measured (Manolio 2009). A primary advantage of cohort design is that it allows avoidance 
of dichotomising phenotypes that reduces the statistical power of GWA (McCarthy et al. 
2008). It is thus particularly useful for analysis of quantitative disease-related traits such as 
body mass index and fasting blood glucose levels. Additionally, environmental exposures 
and other covariates can easily be investigated in this design (Manolio 2009), allowing 
dissection of the relative influences of environmental and genetic factors. 
3.3 Family-based 
Although they require more effort to ascertain, phenotype and sample, family-based studies 
offer many advantages. Using related groups reduces the likelihood of population 
stratification (Hirschhorn et al. 2005; Lasky-Su et al. 2010; Witte 2010), while the increased 
commonality of alleles among families reduces complexity associated with genetic 
heterogeneity. The ability to perform joint linkage and association analysis is another asset 
of a family-based approach (Visscher et al. 2008). Relative to unrelated populations, a family 
study can offer increased efficiency and statistical power per individual genotyped by 
enabling additional pairings such as sibling and parent-child.  General belief that family 
studies offer substantially reduced power compared to unrelated samples (Hirschhorn et al. 
2005; McCarthy et al. 2008; Lasky-Su et al. 2010; Witte 2010) stems from misinterpretation of 
an earlier publication by Risch and Merikangas (Risch et al. 1996) and as explained by 
Blangero (Blangero 2004). Their findings were based on comparison of an ill-advised family 
design with an optimal association design (Blangero 2004). For common complex diseases, 
the statistical power of a more efficient family design can be shown to be similar to GWA of 
unrelated individuals (Figure 1) (Laird et al. 2006). Indeed it has been argued that the 
advantages offered by a related group outweigh the small statistical power lost (Visscher et  
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Fig. 1. The statistical power of GWA for blue case-control compared to red family trio 
(affected child and parents). This is modeled for a disease with 14% prevalence, similar to 
CVD in Australia. It should also be noted that a family design is more powerful for low 
frequency variants. Adapted from(Laird et al. 2006)  
al. 2008). Additionally family designs allow investigation of the influence of parent of origin 
effects of an allele which is being increasingly recognised as an important factor in assessing 
disease risk (Kong et al. 2009; Manolio et al. 2009; Agopian et al. 2011). The finding that 
variants from parental origin are likely to confer increased risk for complex diseases (Kong 
et al. 2009) supports this approach. Despite favour for one or the other (Bell et al. 1997; 
Visscher et al. 2008), complementation of both related and unrelated groups will be 
important for a robust approach. 
4. Limitations of Genome-Wide Association studies 
GWA studies have been an unrefuted success in finding trait/disease-associated SNPs 
(TASs) (Hindorff et al. 2009) and candidate genes, however they have produced 
disappointment in establishing causal variants and disease mediating genes, that has arisen 
in part due to the unexpected complexity of gene transcriptional regulation and variable 
linkage disequilibrium structure. Furthermore, for the overwhelming majority of complex 
diseases studied, the collective effects of associated variants can only explain a small 
proportion of the trait heritability (Manolio et al. 2009). There are several possible 
explanations for this so called "missing heritability" that are further explored in this section.  
4.1 GWA only detects associated loci and not the causal variant directly 
In most cases GWA studies do not directly identify the causal variant. Once a region has 
been characterised as harbouring a causal locus, detailed study of all genetic variants in 
linkage disequilibrium with the TAS is needed to discover the causal variant. This is a 
difficult and time consuming process, and so a candidate gene approach relying on 
previously known functions of neighboring genes and their relationship to the associated 
trait is often used to provide direction. If the TAS lies within a gene coding sequence, 
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causative gene selection can be straightforward, however examples of associated SNPs 
within gene introns regulating another more distant gene show that selection based on 
proximity can by myopic (Jowett et al. 2010; Ragvin et al. 2010). Furthermore it is difficult to 
assign TASs that lie within an intergenic gene desert. Given that approximately 88% of TASs 
are located in intronic and intergenic regions (Hindorff et al. 2009) the process of identifying 
the causal gene is problematic. Table 1 lists how SNP location in relation to gene structure 
may affect a trait influencing gene. 
Once the causal variant is identified, understanding how it contributes to the disease 
phenotype also remains challenging, particularly for non-coding polymorphisms. On 
account of SNP selection on high density SNP chips, GWA studies have driven investigation 
into intronic and intergenic regulation of gene expression. Increased understanding about 
the role of non-coding RNA has also illustrated a means for intergenic variants to influence 
gene expression. Characterisation of intergenic SNPs within long non-coding RNA has 
begun (Pasmant et al. 2011), and may be expected to continue. 
 
Table 1. Potential biological consequences of a genetic variant in relation to its location. 
Examples of these have been described in the following; 1(Hindorff et al. 2009), 2(He et al. 
2009), 3(Rutter 2010), 4(Zhang et al. 2011), 5(Ryan et al. 2010), 6(Cooper 2010), 7(Jia et al. 2009), 
8(Pasmant et al. 2011).  
4.2 GWA cannot discriminate against true and ‘indirect’ associations  
Recently Dickson et al (Dickson et al. 2010) found that the strength of an association signal 
can be strongly affected when there is a large difference in allele frequency between the 
genotyped common tagging variant and causal variant. This concept of a TAS representing 
a diluted signal from a neighboring causal variant was named a ‘synthetic association’ 
(Dickson et al. 2010). The hypothesis proposes that when one or more rare causal variants 
are enriched in a haplotype with a particular allele of the common variant, the association 
may be falsely assigned. This raises the possibility that a common variant association may 
instead represent several rare variants of potentially larger effect, and consequently the true 
www.intechopen.com
 
Genetic Diversity in Microorganisms 314 
strength of the association may have been underestimated. Furthermore these rare variants 
may act over large distances up to megabases to create synthetic associations (Dickson et al. 
2010). This suggests that the region typically selected for re-sequencing (~500kb) may have 
been underestimated, and thus causal variants missed. The synthetic association hypothesis 
is supported by the Crohn’s disease associated loci NOD2 which features three rare coding 
variants that drive a strong association signal at nearby common variants (Wang et al. 2010).  
 
(a) 
 
(b) 
Fig. 2. (a) Synthetic Associations occur when causal rare variants are inherited more 
commonly with one tag SNP allele (e.g. “G”) than the other (“A”) allele (black lines 
represent different individuals). This rare variant may be outside the region of linkage 
disequilibrium defined by the common SNP (shown by the blue box). Adapted from (Cirulli 
et al. 2010). (b) Because the rare variant is too infrequent to be detected by GWAS, the true 
strength of the association signal will be missed. A diluted version of this signal will instead 
be represented by the common variant (Dickson et al. 2010). 
However, debate has arisen over the validity of the synthetic association paradigm and its 
applicability to all common TAS (Orozco et al. 2010; Anderson et al. 2011; Wray et al. 2011). 
Since rare variants are likely to have arisen relatively recently, they are unlikely to be shared 
by divergent ethnic groups. Consequently, common variants that reflect a signal driven by 
rare alleles, or synthetic associations, are also expected to be largely population specific 
(Orozco et al. 2010; Anderson et al. 2011). A locus that harbours a cluster of low frequency 
variants that confer high risk of disease should be amenable to linkage mapping (Orozco et 
al. 2010; Anderson et al. 2011). Therefore, associations that are sensitive to linkage analysis 
but not ethnically replicated potentially represent synthetic associations. In light of 
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widespread trans-ethnic associations and discrepancies between linkage and GWA loci, it 
has been argued that synthetic associations are unlikely to explain the majority of GWA 
signals (Orozco et al. 2010; Waters et al. 2010; Anderson et al. 2011). The hypothesis remains 
to be further evaluated with the aid of high-throughput sequencing efforts (Orozco et al. 
2010). If synthetic associations prove common, commentary about the large role of 
regulatory variants (Hardy et al. 2009; Hindorff et al. 2009) in complex phenotypes may be a 
little premature as non-coding common variants may instead represent a causal variant 
within a coding region megabases away.  
4.3 GWA is limited to common variants  
The limitation of GWA to detecting only common variants is central to literary debate over 
missing heritability sources. In the context of the CDCV hypothesis this was initially a 
logical approach, however large missing heritability for almost all complex diseases (Table 
2) suggest that the CDCV may not be sustainable and that the influence of common variants 
on complex phenotypes has been overestimated. Despite the impressive number of variant 
sites genotyped by high density SNP chips, a full genome wide survey remains incomplete, 
with up to 20% of common SNPs not sufficiently tagged (Frazer et al. 2009). This has arisen 
mainly due to the remarkable and perhaps originally underestimated genetic diversity of 
the human species. Another confounder has been the observed complex patterns of linkage 
disequilibrium (LD), where so called "LD blocks" tend to fragment and fail when lower 
frequency variants are considered. The result is that for the most part, lower frequency 
variants are missed by GWA studies. Inability to detect these low frequency variants has 
been suggested widely in the literature as contributing significantly to missing heritability 
(Hirschhorn et al. 2005; Hardy et al. 2009; Manolio et al. 2009; Manolio et al. 2009; Schork et 
al. 2009; Cirulli et al. 2010; Dickson et al. 2010; Park et al. 2010). In this context the potential 
for rare variants with moderate effect sizes to influence common disease has been 
recognised (Manolio et al. 2009; Schork et al. 2009; Carvajal-Carmona 2010). Furthermore 
this paradigm has been suggested as more consistent with evolutionary genetics where less 
harmful variants with smaller effect sizes remain under less pressure from the action of 
negative selection and are therefore more likely to be common (Schork et al. 2009).  
 
Table 2. Despite large numbers of associated loci identified, many complex diseases and 
traits have only a small proportion of heritability explained. Heritability is the proportion of 
phenotype explained by genetics.1 (Burren et al. 2011), 2(So et al. 2011), 3(Clayton 2009), 
4(Kooner et al. 2011), 5(Parra et al. 2011), 6(Imamura et al. 2011), 7(Fransen et al. 2011), 8(Zhao 
et al. 2010), 9(Yang et al. 2010). 
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4.4 Missing heritability  
Despite numerous GWA studies and the identification of dozens of trait associated variants 
for each complex disease, a large proportion of heritability remains unexplained for almost 
all complex phenotypes examined (Table 2). The study of height illustrates the gap between 
discovered and estimated heritability. Extensive GWA has revealed 51 loci significantly 
associated height, a complex trait with high heritability of 0.80, yet these variants combined 
only explained 5% of the heritability (Yang et al. 2010; Zhao et al. 2010). The small 
contribution of these common variants to complex phenotypic variance has also limited 
utility of these markers for disease predication (Hirschhorn 2009). If the proportion of 
heritability explained is regarded as a measure of the success of the GWA approach, then its 
performance in elucidating complex disease genetics may appear underwhelming. However 
against the backdrop of many additional contributing factors such as rare variants, copy 
number variants, epigenetic modifications and epistasis, the achievement of the GWA 
approach can be considered solid progress. 
4.4.1 Copy number variants  
Copy number variants (CNVs) including insertions and deletions ranging from a few bases 
up to megabases in size have been highlighted as having potential to contribute to complex 
phenotypes (Frazer et al. 2009; Manolio et al. 2009; Cirulli et al. 2010). A broad study across 8 
complex diseases by the Welcome Trust Case Control Consortium using existing datasets to 
tag CNVs found that for those CNVs typable on the employed platforms, they were unlikely 
to play a major role in the determination of the genetic basis of common diseases (Craddock 
et al. 2010). A key caveat as highlighted in the study was what could be measured by the 
SNP chip platforms. As noted by Alkan et al (Alkan et al. 2011), these platforms fail to detect 
CNV's less than 500 bp in size. These small CNVs thought to arise during recombination 
events and consequently are both difficult to detect and difficult to genotype. However, new 
sequencing data is emerging showing that this class of small CNV is not only pervasive but 
also likely to contribute significantly to disease risk. Therefore it is too early to dismiss the 
potential contribution of CNVs to complex disease development. 
4.4.2 Epigenetics  
Heritable epigenetic modifications to DNA and histones may be another potential 
contributor to complex disease processes (Bell et al. 2011). Epigenetic marks include post-
translational modification of histones, non-coding RNA and DNA methylation (Rakyan et 
al. 2011). Epigenetic reprogramming of zygotes is used in arguing against meiotic 
transmission of epigenetic states, however several observations suggest that retention is 
possible (Rideout et al. 2001; Rakyan et al. 2003; Blewitt et al. 2006; Bell et al. 2011). Results 
from the study of monozygote twins show that they have more similar epigenetic profiles 
relative to dizygotic twins (Fraga et al. 2005). A complicating factor for investigation of 
epigenetic changes is that they are often tissue specific. Unlike GWA studies where most 
tissues are suitable for identifying germ line genetic variation, easily accessible samples such 
as blood may not efficiently reflect robust epigenetic alterations in other tissues that carry an 
impact on disease development. Since many tissue types that are important to disease 
development are effectively inaccessible due to unacceptable risks to the patient, such as 
brain, the development of comprehensive epigenetic profiles may be limited. Furthermore, 
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intra tissue heterogeneity presents an additional complication where a tissue, such as 
adipose, may be infiltrated with other cell types such as macrophages as observed in states 
of obesity. Reliable solutions that resolve these confounding issues are yet to be developed. 
4.4.3 Environment 
Phenotypic variation is traditionally considered as a result of two sources of variation; 
genetic and environmental (Richards 2006). While the magnitude of environmental effects 
on complex disease is disputed (Hardy et al. 2009; Rappaport et al. 2010), their influence on 
common disease development is generally accepted (Bell et al. 1997; Manolio 2009; Manolio 
et al. 2009; Cirulli et al. 2010). It has been proposed that the smaller the odds ratio, the more 
likely that environmental factors predominate (Bodmer et al. 2008) and hence a need for a 
more comprehensive measure of environmental exposure and its interaction with genetic 
variants is required (Hemminki et al. 2006; Murcray et al. 2009; Eichler et al. 2010; Rappaport 
et al. 2010). However if a study does record environmental factors they are usually by 
participant self report and can be biased by inaccurate and variable recall, leading some 
researchers to dismiss their inclusion as they generate too much noise. It is therefore not 
surprising that gene-environment interactions are currently poorly understood.  
The novel characterisation of the ‘exposome’ by Rappaport and Smith (Rappaport et al. 
2010) provides a basis to explore gene-environment interactions. The exposome represents 
all exposures that impact the internal chemical environment of humans (Rappaport et al. 
2010). GWA studies have the potential to identify SNPs that demonstrate heterogeneity 
between subgroups defined by an environmental exposure (Murcray et al. 2009) and could 
potentially reveal loci that might otherwise have been dismissed. A good starting point for 
maximising GWA information about gene-environment interactions is to perform 
environmental-wide association studies as undertaken by Patel et al (Patel et al. 2010). This 
approach using exposome biomarkers can be used to propose novel environmental factors 
for further study, such as ┛-tocopherol which was positively associated with type 2 diabetes 
risk (Patel et al. 2010). Notably ┛-tocopherol is the most abundant component of Vitamin E 
in the US diet, and represents up to 50% of total Vitamin E in insulin-target tissues (Patel et 
al. 2010) making it a plausible candidate. A GWA study with ┛-tocopherol may reveal 
candidates for gene-environment interaction points.  
Evidence has shown that the environment can trigger heritable epigenetic changes (Jirtle et 
al. 2007; Ng et al. 2010) however this requires more investigation to determine the extent of 
influence on gene expression. Indeed it has been argued that GWA studies might be 
misleading without consideration of environmental factors (Bell et al. 1997). Additionally 
the observation that some environmental risk factors can have a ‘heritable’ component, such 
as a heritability estimate of 0.6 for regular tobacco use (Kendler et al. 2000), suggests that the 
environmental component of complex disease can be "contaminated" with heritability 
arising from behavioral and risk taking psychological traits (Petronis 2010).   
4.4.4 Is the metric wrong? 
Realisation that epigenetic variation can contribute to complex phenotypic variation 
(Richards 2006; Petronis 2010; Bell et al. 2011) has important implications for heritability 
estimates. Discussion around the potential for human transgenerational epigenetic 
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inheritance (Richards 2006; Petronis 2010; Bell et al. 2011; Rakyan et al. 2011)  has suggested 
that the genetic contribution to complex phenotypes may have overestimated. Therefore 
attributing heritability estimates solely to genetic variants may be short sighted if epigenetic 
marks are significantly heritable, as Slatkin suggests (Slatkin 2009). Heritability can differ 
temporally and between environments (Heath et al. 1998; Turkheimer et al. 2003; Visscher et 
al. 2008) implying that dissecting phenotypic variation is not as simple as currently treated. 
Daily variance in some traits such as blood glucose and difficulty in standardising 
measurement have also contributed to variable estimates of trait heritability. However on 
balance, the estimates today are not likely to be sufficiently far from the actual so as to 
remove all of the missing heritability for complex diseases. 
 
Fig. 3. Heritability estimates represent the genetic variation contributing to phenotypic 
variation and may be considered as divisible into 3 components; epigenetic, ‘direct’ genetic 
and ‘indirect’ genetic. Epigenetics and ‘direct’ genetics influence the phenotype directly, 
whereas ‘indirect’ genetics represent the heritable portion of behaviours that contribute to 
environmental influences, such as heritability of regular tobacco use. The environment may 
induce epigenetic changes suggesting that the two traditional components of phenotypic 
variance, namely the environment and the heritable portion, may not be wholly distinct.  
4.4.5 Epistasis 
The extent of missing heritability encouraged revision on the factors that influence genetic 
effects on disease development. Epistasis in genetics is defined as the interaction between 
genes; a phenomenon where one gene influences the expression of another. For example the 
E4 allele of the apolipoprotein E (ApoE) gene is associated with increased serum cholesterol 
levels, but only when the individual possesses the A2A2 genotype of the low-density 
lipoprotein receptor (LDLR) gene (Tyler et al. 2009). ApoE’s phenotypic effect thus depends 
on the LDLR locus. Epistatic effects amplify the complexity between genotype and 
phenotype, suggesting that the combination of genotypes inherited may be instrumental to 
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disease risk (Moore et al. 2009), and it has been argued that epistasis is likely to be a ubiquitous 
component of the genetic architecture of common complex disease (Moore 2003; Moore et al. 
2009). Humans have evolved robust biological systems that use network redundancy to confer 
resistance to genetic or environmental fluctuations (Moore et al. 2009). Disease could be 
perceived as an accumulation of parallel pathway ‘breakdowns’, whereby an important 
pathway and all of its ‘backups’ become dysfunctional. In this context, the particular 
combination of alleles inherited will determine disease phenotype. This concept could explain 
failure to replicate significant SNP associations and the low effect sizes of each. When 
considered in a multilocus model, a variant may exert a larger effect than estimated with a 
single locus approach (Wang et al. 2005). Indeed a “genometype” as proposed by Moore 
(Moore 2009) would ideally be considered as a basis for calculating clinical risk. 
The computational burden associated with statistical analysis of epistasis on a genome-wide 
scale is unfortunately a limitation in dissecting complex disease genetics. To consider all 
possible pair-wise interactions alone, approximately 500 billion SNP-pairs would have to be 
examined (Zhang et al. 2011). Development of efficient two-locus epistasis tests has been 
challenging as reflected in a recent study by Bell et al (Bell et al. 2011). A two-locus analysis on 
type 2 diabetes GWA data identified 79 significant pair-wise results, but all included a TCF7L2 
SNP which was the most significant in a single-locus analysis. It was realised that the strong 
TCF7L2 signal was driving the two-locus significance results, ultimately obscuring multilocus 
findings and signaling a hurdle for such analysis. The complex computation for investigation 
of genome wide epistasis therefore remains a significant challenge.  
5. Approaches to addressing GWA limitations  
Despite its shortcomings, GWA studies have produced data that is rich in information. 
Further optimisation and re-analysis may yield additional insights from this approach while 
identification of disease genes within the loci is expected to improve current understanding 
of complex disease development.  
5.1 Transcriptome analysis enables prioritisation of candidate variants 
Considering that most trait associated loci feature variants that do not affect protein sequence, 
it is anticipated that many of these loci have a regulatory role on gene expression (Heap et al. 
2010), although as discussed above this assumption may be somewhat premature. Genomic 
regions that contribute to phenotypic variation by influencing transcription, mRNA stability 
and splicing are termed expression quantitative trait loci or eQTLs (Heap et al. 2010). 
Integration of expression profiles with GWA data can reveal eQTLs by identifying transcripts 
that correlate with the TASs (Figure 4). This approach allows empirical ranking of juxtaposed 
candidate disease-mediating genes that can be taken forward into in vitro and in vivo 
functional biological assays to determine the role and mechanism in the disease process. 
Translation of these eQTLs into enhanced biological knowledge of disease has been seriously 
impeded by the dearth of large scale human datasets that carry both genetic and transcript 
data from the same individual that facilitate identification of the disease mediating gene(s) 
(McCarthy et al. 2008). However some datasets do exist and a demonstration of this approach 
has been reported where variants in an intronic region of FTO were found to be strongly 
correlated with gene expression of a more distant gene RBL2 (Jowett et al. 2010). Similarly, 
approaches relying on conservation of synteny and nucleotide sequence among vertebrate  
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Fig. 4. GWA has found the circled SNP to be associated with a disease. It can be difficult 
though to assign this SNP to a candidate gene. Transcriptome analysis can make this easier 
by comparing the expression levels of flanking genes to each other, and between affected 
and unaffected individual. The decreased expression of gene 1 is associated with the 
disease, suggesting that gene 1 is the better candidate gene. 
species have highlighted a second gene IRX3 flanking FTO that may contribute to disease 
processes (Ragvin et al. 2010). Further function validation is required to resolve the relative 
contribution of these genes at this locus.  
The study of eQTLs has shown that they generally explain a greater proportion of the 
phenotype than risk alleles (Freedman et al. 2011), suggesting that consideration of 
expression data may uncover missing heritability. It has also reinforced that eQTL 
associations can be tissue-specific (Freedman et al. 2011), differ between in vivo and in vitro 
systems and also between cell types (Goring et al. 2007; Farber et al. 2009; Hardy et al. 2009). 
Evaluation of expression profiles using a single platform for liver, adipose tissue and blood 
showed a 30% overlap in the three tissues (Nica et al. 2008). This observation suggests that 
there is value in using any available transcriptome data set for analysis, but also highlights 
that the majority of expression patterns might be tissue-specific (Nica et al. 2008). The 
present lack of a comprehensive data set detailing expression profiles of normal tissues calls 
for caution in interpreting significant associations derived from tissue–specific expression 
data. This issue has encouraged the Genotype-Tissue Expression project, an idea which was 
pre-empted in the literature (Goring et al. 2007; Nica et al. 2008). Allelic-specific expression 
can be used to characterise an eQTL in an individual heterozygous for the risk allele and 
offers a means of avoiding sources of error that can confound assessment of expression 
profiles across multiple individuals (Heap et al. 2010). Gene expression can also differ 
temporally, especially for developmentally important genes. Model organisms such as the 
zebrafish have utility in investigating the effects of non-coding elements on gene expression 
in a particular context (Ragvin et al. 2010). Defining the appropriate tissue and time point to 
glean human expression data from is not clear, and is an area earmarked for further 
development (Freedman et al. 2011).  
5.2 A wider region should be considered for fine mapping  
Identification of synthetic associations discussed above has shown that a wider region 
encompassing the TAS should be considered during fine mapping. If rare variants can act 
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over megabase distances to drive an association signal (Dickson et al. 2010), then the 
average region size selected for investigation (~500kb) may be too narrow to capture causal 
variants. This approach may increase the explained heritability for complex phenotypes as 
the combined influence of multiple rare variants could exhibit a larger effect collectively 
than the synthetically associated common variant (Dickson et al. 2010) where the effect size 
has eroded due to distance and LD. Following up on non-reproducible common associations 
and loci that have known linkage peaks within a few megabases might increase the 
likelihood of finding a causal variant.  
5.3 Integrate with Epigenetic-Wide Association studies  
Recent technology advances have allowed contemplation of epigenome-wide association 
(EWA) studies (Rakyan et al. 2011), where up to 450,000 DNA methylation sites can be 
measured on a single chip. Although the primary focus of the analysis of these results will 
be on DNA methylation, there is evidence to suggest that information might be obtained on 
other epigenetic marks such as histone modifications (Bernstein et al. 2007) and can thus 
have a broader application. Development of epigenetic maps by the International Human 
Epigenome Consortium (Rakyan et al. 2011) will empower EWA synonymous to the utility 
of the HapMap in GWA studies. Additional insights might arise where loci harbouring 
genetic variation influence the methylation state of the region (methQTLs) (Rakyan et al. 
2011). Therefore there is potential utility in combining data from GWA and EWA studies as 
illustrated by a recent study where a haplotype-specific DNA methylation locus for a type 2 
diabetes risk variant was identified (Bell et al. 2010).  
While EWA holds great promise for revealing genetic architecture of complex disease, it also 
presents unique challenges. A significant difference from GWA is that epigenetic association 
with a phenotype can be causal as well as consequential (Rakyan et al. 2011). Although this 
adds another layer of complexity to EWA analysis, it can be dissected by appropriate study 
design. Randomly ascertained longitudinal cohort studies will be integral to determining 
the temporal origins of the reported epigenetic association and elucidating whether its 
origin is pre or post onset of the phenotype (Rakyan et al. 2011). Furthermore with thorough 
detailing of environmental changes, this study design may reveal an environmental cue for 
epigenetic change. However this presents a double-edged sword, with environmental 
factors such as smoking able to confound EWA (unlike GWA) and inflate effect size 
estimates (Rakyan et al. 2011). Additionally ascertainment, phenotyping and sample 
collection of a large cohort as would be required for such a study is not a trivial 
undertaking. Looking at this issue from another perspective, it presents a means to 
investigate environmental backgrounds which increase epigenetic risk variants. Such 
information has scope for application in a clinical setting, and could be useful in 
encouraging behavioral changes in patients with a ‘vulnerable’ epigenetic locus.  
5.4 Reduce statistical rigour  
The statistical rigour applied to GWA study data analysis has been suggested as potential 
explanation for the observed missing heritability (Yang et al. 2010). Variants with weak but 
relevant effect sizes which fall under stringent thresholds resulting from adjustment for 
multiple testing may potentially be excluded from analysis to reduce the false positive rate. 
While commonly each TAS is evaluated individually, Yang et al considered a model that 
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evaluates the variance explained by a group of TASs collectively (Yang et al. 2010) using a 
software program that estimated the variance explained by the group on a chromosome or 
on the whole genome (Yang et al. 2010). Application of this approach to human height GWA 
studies revealed that as much as 40% of missing heritability may be found by such 
accumulation of the variance explained (Yang et al. 2010). The biological plausibility of 
considering ~300,000 loci to influence this trait is debatable. However the principal has been 
demonstrated and further functional studies are required to empirically determine 
appropriate statistical rigour that may differ from one phenotype to the next. Application to 
predict disease onset found improvement with the whole genome method (Makowsky et al. 
2011), however genotyping thousands of variants is unlikely to be sufficiently cost effective 
and carry a substantially large clinical benefit to warrant its widespread use. 
5.5 Increase study size 
Even a relatively large GWA study (5000 cases and 5000 controls) has relatively low power 
to detect an association; 0.9% at a P-value of 10-7 (Kraft et al. 2009). Therefore increasingly 
large cohorts have been studied in addition to the combining existing sets into the meta-
analysis studies (Zeggini et al. 2008; Barrett et al. 2009; Park et al. 2010). While this has been 
productive to an extent, increasing size also increases the potential for increased genetic 
heterogeneity and thereby raises the background noise level. Additionally since such large 
cohorts are impractical to collect from a single clinic or site, they must be undertaken at 
multiple participating centers that increase the chance for differences in phenotyping 
accuracy. The point at which additional loci might be discovered against increasing amount 
of background noise might have been reached as demonstrated by a recent GWA study for 
central obesity and fat distribution using waist and waist-hip measurements. The cohort 
consisted of ~100,000 participants, but the results yielded only three associated loci, with 
each explaining a mere fraction (0.05%, 0.04% and 0.02%; combined total 0.11%) of the total 
trait variance (Lindgren et al. 2009).  
An alternate to increasing study size is to increase diversity, that is to undertake similarly 
sized GWA studies in a range of diverse ethnic groups. It has been established that some 
SNPs are population specific (2010) and that any given variant may show a different effect 
size between differing ethnic groups (Dickson et al. 2010). Since many GWA studies had an 
initial focus on European populations, examining non-European groups may reveal 
additional loci. Such studies are now starting to appear and have successfully identified new 
sets of loci (Kooner et al. 2011; Parra et al. 2011). While it is apparent that a causal variant 
may not be consistently associated among different populations due to unique genetic and 
environmental factors, a population-specific variant should also not be discounted as having 
limited clinical application. This is because of the commonality of intra- and inter-cellular 
molecular pathways in humans. That is any loci leading to identification of a disease gene 
will reveal a pathway that will be present across all members of the species, and as such is 
expected to have broad application. 
The observed missing heritability suggests that many inherited factors remain to be 
discovered. For example, if further pursuing common variants, a crude statistical estimate 
suggested that there may be up to 800 additional variants yet to be discovered for type 1 
diabetes (So et al. 2011). However Goldstein argues that analytical approaches based on 
discovery of common variants have been exhausted and that if any loci are left to discover, 
it will not be worth the time and cost of ever larger studies to detect them (Goldstein 2009). 
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This stance is supported by Park et al who proposed that additional loci discovered in larger 
studies will generally have smaller effects (Park et al. 2010) and therefore may be limiting 
for detecting large effect variants. Such estimates have provided additional momentum to a 
paradigm shift that analysis of complex disease should be redirected toward rare variants 
with potentially large effects.  
6. Case study: Type 2 diabetes 
The pursuit for genetic factors that underlie Type 2 Diabetes (T2D) encapsulates the 
challenges and rewards of GWA studies. Almost 350 million people suffer from diabetes 
mellitus, with approximately 90% of those having developed T2D specifically (Danaei et al. 
2011). Characterised by insulin resistance and abnormal beta-cell function (Imamura et al. 
2011), the genetic contribution of T2D was well established by family and twin studies 
(Groop et al. 1996; Poulsen et al. 1999). Current heritability estimates for T2D predict ~40% 
of the phenotype is explained by genetics (So et al. 2011).  
With the incidence and consequent economic impact of this common complex disease 
projected to increase considerably (Colagiuri 2010), there has been a strong focus on 
identification of the genetic basis of T2D development. Although GWA has facilitated the 
identification of over 45 genetic susceptibility variants (Kooner et al. 2011), the promise of 
clinical application remains unfulfilled.  
6.1 The GWA study boom 
Prior to the advent of GWA studies, linkage analysis and candidate gene studies were used 
to discover loci associated with T2D. Despite extensive efforts spanning a decade (Frayling 
2007) progress was slow. Notable achievements included identification of PPARG and 
KCNJ11 as candidate genes (Altshuler et al. 2000; Gloyn et al. 2003), and TCF7L2 as the 
common variant driving linkage at a T2D risk gene region (Grant et al. 2006). Additionally 
linkage analysis identified several hundred loci, of which over 50 were replicated by 5 or 
more independent studies (Lillioja et al. 2009). As GWA studies emerged from 2007, a 
sudden increase of T2D associated loci followed, reflecting the potential of GWA to provide 
genetic clues of disease etiology (Table 3).  
6.2 The role of epigenetic modification 
As has been observed with almost all complex diseases, only ~10% of the heritability can be 
explained despite over 45 associated loci reported (Imamura et al. 2011). As discussed 
above, there are several possibilities that may explain the missing heritability including rare 
variants, copy number polymorphisms and inherited epigenetic polymorphisms. Epigenetic 
modification as a result of environmental influences and in particular the fetal environment 
has been highlighted as having potential to predispose to T2D (Ling et al. 2009; Liguori et al. 
2010). The Dutch Hunger Winter Study revealed an association between prenatal exposure 
to famine and decreased glucose tolerance (Ravelli et al. 1998). Effects on methylation were 
also investigated with all but one famine exposed individual showing significant 
hypomethylation of the known T2D candidate gene insulin-like growth factor 2 (IGF2) 
relative to their unaffected sibling (Heijmans et al. 2008). This example highlights the 
vulnerability of the fetal genome to the prenatal environment, and the ability of epigenetic 
changes to persist between generations.  
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Table 3. Top ranking candidate genes for type 2 diabetes as per estimated effect size. Odds 
ratio’s as listed in (Imamura et al. 2011).  
6.3 The slow walk from association to mechanism 
While T2D GWA studies have been successful for revealing associated loci, it has proved 
difficult to understand the mechanisms through which these loci mediate their biological 
consequences. Here we examine this aspect of translation of GWA identified loci to useful 
biological knowledge using several examples to illustrate.  
6.3.1 IGF2BP2 
An intronic locus within translation regulator IGF2 mRNA binding protein IGF2BP2 was 
significantly associated with T2D, implicating IGFBP2 and supporting the candidacy of IGF2 
and its regulation in T2D. Previously unpublished data using transcriptome analysis 
combined with genetic variation data in a large human cohort showed a nominally 
significant association between IGFBP2 and the intronic TAS supporting the hypothesis that 
this locus mediates its effects through regulating the expression of IGFBP2 (Figure 5). The 
methodology for this analysis was as reported for the FTO loci by Jowett and colleagues 
(Jowett et al. 2010). Investigation of top T2D GWA candidates in the Dutch Hunger Winter 
cohort showed that IGF2BP2 variants were most strongly associated with increased risk of 
T2D, impaired glucose tolerance and area under the curves (AUC) for oral glucose tolerance 
testing (OGTT) (van Hoek et al. 2009). The presence of the IGF2BP2 risk allele in those 
exposed to famine was nominally significantly associated with lower AUC for glucose. That 
two factors which confer risk to T2D are together associated with increased glucose uptake 
may seem contradictory, but in light of a similar observation for another risk allele (van 
Hoek et al. 2009) this can be explained. IGF2BP2 variant may instead represent a protective 
allele, acting to repair the detrimental consequences of fetal malnutrition on glucose 
tolerance in later life (van Hoek et al. 2009). IGF2BP2’s mode of action in T2D development 
is still unclear, with recent research revealing its capacity to both initiate and repress  
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(a) 
 
(b) 
Fig. 5-a. Association of the rs4402960 SNP with the expression levels of genes within 5Mb of 
the SNP coordinate. Strong association of the IGFBP2-residing SNP with IGFBP2 is 
observed, suggesting that this locus mediates its effects through IGFBP2 regulation of 
expression. 5-b. Association of the rs1111875 SNP with the expression levels of genes within 
5Mb of the SNP coordinate. Strong association of the SNP with HHEX is observed, 
suggesting that this loci mediates its effects through HHEX regulation of expression. The 
intron/exon structure of the genes in this region is illustrated by the lines and blocks 
beneath the x-axis (thin line, intron; block, exon). The negative log of the P-value is plotted 
against the coordinates in megabase pairs (Mb). The methodology for this analysis was as 
reported for the FTO loci by Jowett and colleagues (Jowett et al., 2010). 
translation of targets (Boudoukha et al. 2010; Dai et al. 2011). This reported association 
between IGF2 hypomethylation and IGF2BP2 risk variant suggests scope for an increased 
risk in an individual that possesses both marks. Investigation of IGF2 expression levels in 
the Dutch Winter Cohort may provide insight into IGF2BP2’s role by reporting a condition 
that exacerbates the variants risk effects.  
6.3.2 HHEX-KIF11-IDE 
The HHEX-IDE-KIF11 locus encompasses an extended region of high linkage disequilibrium 
spanning three genes, two of which were considered plausible candidates; the homeobox 
HHEX transcription factor involved in pancreatic development (Prokopenko et al. 2008) and 
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the insulin degrading enzyme IDE. Two different approaches suggested that the locus might 
regulate HHEX expression as the mediator of its biological consequences (Ragvin et al. 2010) 
(Jowett unpublished). As described above, relying on a large human cohort with 
transcriptomic and genetic variation data, we observed that HHEX was the most strongly 
associated transcript with the associated variant. IDE was not associated, while KIF11 was 
not within detectable limits of expression and could not be commented on further. In the 
second approach it was observed that the TAS for this locus was within a highly conserved 
noncoding element (HCNE) exhibiting synteny between a number of vertebrate species 
including mouse, chicken, frogs and zebrafish (Ragvin et al. 2010). Subsequent reporter gene 
studies of the enhancer region found that expression was specific to the pancreatic islet cells 
in a zebrafish model (Ragvin et al. 2010). However there is also evidence for a role for IDE in 
T2D development (Farris et al. 2003; Pivovarova et al. 2009), suggesting potential for an 
associated locus to modulate expression of more than one gene in the region.  
6.3.3 CDKN2A-CDKN2B 
With the intergenic SNP lying 125kb upstream of the closest protein-coding gene, the 
CDKN2A-CDKN2B locus also demonstrates a difficult scenario for assigning a candidate 
gene. These genes encode cyclin-dependent kinase inhibitors known to have an important 
role in ┚-cell function and regeneration (Bao et al. 2011), and thus are plausible biological 
candidates for T2D. This SNP is not lost in the ‘gene desert’, but rather it maps to a long 
non-coding RNA ANRIL, which lies anti-sense to CDKN2B and has been shown to have a 
pivotal role in regulating CDKN2A/B expression in mice (Pasmant et al. 2011). ANRIL 
achieves this by interacting with polycomb repressive complexes to form heterochromatin at 
the locus, ultimately leading to its repression (Aguilo et al. 2011). Given that over expression 
of the CDKN2A orthologue in a rodent model induces a T2D phenotype (Krishnamurthy et 
al. 2006), the regulatory action of ANRIL is likely important in T2D development. As more is 
learnt about the abundance and function of non-coding RNAs in general, it may not be 
unexpected that this mode of regulation might apply in more  GWA loci where there are no 
obvious candidate genes (Pasmant et al. 2011). 
6.3.4 TCF7L2 
The TCF7L2 intronic SNP association is highly replicated and carries one of the largest effect 
sizes of all GWA loci identified to date. Possessing two risk alleles increases T2D risk by 80% 
(Florez et al. 2006). The loss of TCF7L2 has been observed to induce impaired ┚-cell function 
and apoptosis (Shu et al. 2008; da Silva Xavier et al. 2009), providing an explanation of its 
effect on T2D development. Paradoxically, decreased protein levels in diabetic islets were 
correlated with increased TCF7L2 transcript levels (Le Bacquer et al. 2011). Correlation of 
the risk allele with a ‘more open’ chromatin state and enhanced access for transcriptional 
machinery (Gaulton et al. 2010) may provide a possible explanation for observed increase in 
mRNA (Billings et al. 2010), but how reduced protein levels result from increased mRNA 
expression remains to be explained. Reports that different isoforms may exert opposing 
effects on ┚-cell survival (Le Bacquer et al. 2011) may contribute to an explanation of this 
paradox. Future experiments to measure the relative expression levels of the pro and anti-
apoptotic splice variants in islet cells from people with diabetes may be informative. TCF7L2 
illustrates that understanding a strong candidate gene’s role in disease pathogenesis can be 
difficult, even despite extensive effort.  
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As further mechanistic work progresses providing biological information of which genes 
mediate the consequences of genetic variation and how this happens, links between these 
genes may become apparent thus revealing potential insight into networks and pathways 
that control disease mechanism. For example, IGF2 has been shown to compete with insulin 
as an IDE substrate (Misbin et al. 1983; Ding et al. 1992), and thus IDE is likely to act in the 
same pathway as IGF2BP2. Additionally, HHEX and TCF7L2 are both targets of the WNT 
signaling cascade (Frayling 2007) and may operate collectively on the output of this 
pathway. Such commonality of pathways between T2D associated loci highlight the 
potential for a broader understanding of the etiological basis of an association, and provide 
a rationale for direct testing for evidence of genetic interaction.  
 
Table 4. Analysis of GWA data has been challenging. Approaches to overcoming these 
limitations for type 2 diabetes loci may be useful for other TASs.  
6.4 The rewards of GWA studies 
Despite the numerous loci identified by GWA studies, translation of this data into novel 
therapeutics and risk prediction tools has been slow. The primary cause has been difficulty 
in establishing the disease mediating gene, where in many cases annotation by proximity 
can be misleading. Even with a clear understanding of causality, a gene product may not 
necessarily represent a chemically tractable drug target. Characterisation of T2D locus 
SLC30A8 represents a potential exception, where the associated SNP encoded a missense 
mutation (Arg  Trp) in the C-terminus of the protein (Rutter 2010). SLC30A8 encodes a 
zinc transporter involved in insulin storage and secretion (Imamura et al. 2011) and has also 
been implicated in type 1 diabetes (Wenzlau et al. 2007). A person with two copies of the 
risk allele experience a 53% increased risk of developing diabetes (Rutter 2010) most likely 
due to reduced transporter activity. A drug that enhances the activity of this transporter 
may potentially increase insulin secretion and thus lower blood glucose levels (Imamura et 
al. 2011), however chemical agonists are harder to develop then antagonists, thus the 
prospect of new drugs from this research remains confined to the future.  
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The use of T2D risk alleles in disease prediction to date has also found limited utility in 
clinical practice. Adding a genetic risk score to established prediction models based on 
clinical traits such as BMI and family history showed only limited improvement in 
predictive power (Lyssenko et al. 2008) and is not sufficient to warrant the additional cost of 
genotyping. Other studies (de Miguel-Yanes et al. 2011) have suggested that such clinical 
applications might carry relatively greater benefit for younger people since they may not 
have developed age-dependent clinical risk factors such as hypertension and dyslipidemia. 
Discussion about the potential for a genetic risk score alone to influence healthy patients to 
make lifestyle changes (Grant et al. 2009) suggests that using raw information may be an 
attractive alternative to producing numerical scores. Clearly there is some way to go before 
results from GWA studies can be used to their full fruition, but the progress in risk loci 
characterisation gives hope that novel insights will be gained with potential benefits 
eventually feeding into clinical practice.  
7. Future direction: Common Disease-Rare Variant hypothesis 
In light of the large proportion of unexplained heritability for most common complex 
diseases, new tactics have been employed to advance its genetic characterisation. The 
Common Disease-Rare Variant (CDRV) hypothesis has become the most attractive theory 
for explaining the failures of GWA studies (Nielsen 2010). This model proposes that rare 
variation is the major contributor to complex diseases, with genes or genomic regions 
potentially harbouring many different rare variants (Schork et al. 2009). In contrast to the 
CDCV, rare variants are expected to have arisen relatively recently, or have become rare due 
to negative selection (Schork et al. 2009). Therefore the Multiregional evolution hypothesis 
that describes multiple founder groups contributing to the origin of modern humans is 
supportive of the CDRV rather than the Out of Africa model (Iyengar et al. 2007). Candidate 
genes proposed by GWA for type 1 diabetes (Nejentsev et al. 2009), hypertriglyceridemia 
(Johansen et al. 2010) and Crohn’s disease (Momozawa et al. 2011) have been found to 
harbour rare missense mutations, highlighting the plausibility of the CDRV theory. 
Particularly alluring is that less frequent variation is more likely to be functional (Schork et 
al. 2009). Indeed the majority of rare (<1%) missense mutations present in humans are 
somewhat deleterious in nature (Kryukov et al. 2007), providing hope that rare variants will 
carry larger effect sizes and hopefully more obvious in mechanism than the often cryptic 
common variation.  
7.1 New approaches 
Despite claims that expectations for finding missing heritability of complex disease in rare 
variants may be overoptimistic (Carvajal-Carmona 2010), recent studies have highlighted 
the promise of the study of rare variants in complex disease (Bowden et al. 2010; Holm et al. 
2011). DNA sequencing is the most efficient method for the identification of rare variants 
and while only a few years ago this would be impractical due to costs and time for large 
sample numbers, the advent of next generation sequencing technologies has bought this 
approach into the realm of possibility (Ng et al. 2009; Cirulli et al. 2010; Nielsen 2010). To 
capture all genetic variation, whole-genome sequencing (WGS) would be the preferred 
approach and has already found utility in characterisation of rare monogenic disease (Choi 
et al. 2009). While WGS costs are becoming more affordable, they remain impractical for 
large sample sizes, prompting development of sequencing approaches that will reduce costs 
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such as target enrichment and sample multiplexing. Cohort design for rare variants also 
forms an important consideration, with large extended pedigree designs offering the most 
efficient method for generating sufficient copies of the rare variant to undertake meaningful 
statistical analysis. These strategies (Figure 6) will represent the next stage of genetic 
dissection for complex diseases. 
 
Fig. 6. Until WGS is affordable, alternatives such as exome sequencing, low-coverage WGS 
and smaller sample sizes reduce costs for a sequencing approach. 
7.1.1 Exome sequencing 
The exome (all genomic coding sequence) represents approximately 2.3% of the genome 
(Lehne et al. 2011) and is the genomic region most likely to harbour variants of large effect. 
Consistent with this has been the experience from GWA studies where stronger association 
signals for coding variants than non coding variants have been reported (Lehne et al. 2011). 
Given its smaller size it is also less expensive and faster to sequence than the whole genome 
allowing a large number of samples to be analysed and increasing statistical power for 
evaluation of effects. Successful identification of rare causal variants by this approach has 
been recently reported for several Mendelian diseases (Ng et al. 2010; Ng et al. 2010) and 
also for complex disease traits (Bowden et al. 2010) and disorders (Sanders 2011). However 
focusing solely on the exome ultimately ignores the majority of the genome where 
regulatory variation is located. Sequencing exomes in blocks that include flanking regions 
can increase genome coverage, with 40kb flanks equating to 34% of the genome (Lehne et al. 
2011). The size of the flanking region considered will be cost-limited, but a focus on 
annotated regulatory elements could be used in a gene specific manner and customised to 
limit the amount of sequence required and reduce costs (Lehne et al. 2011). Ultimately 
exome sequencing is considered a temporary measure for making advances before the cost 
of WGS becomes affordable.  
7.1.2 Low-coverage whole-genome sequencing  
Another approach for reducing costs is to sequence genomes at reduced coverage, with only 
250 samples required to find 99% of synonymous variants (2010). Although this technique 
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still allows a genome to be sequenced several times, there may be incomplete genome 
coverage and an expected increase in error rate (Nielsen 2010). It has been noted that 
marginal increase in error rate of only a few percent can equate to substantially reduced 
statistical power (Nielsen 2010). Computational biology approaches, such as imputation, 
uses the data from sequenced individuals to infer the identity of missing nucleotides in a 
new data set, and has been shown to increase the statistical power of GWA studies (Nielsen 
2010). Imputation accuracy decreases parallel to the variant’s frequency, with an error rate 
of 35% reported for minor alleles observed only twice in a low-coverage sample (2010). 
However the increased risk of pursuing a typing error variant is of concern, especially for 
cohorts of unrelated individuals. Family cohort based designs are superior in this regard as 
genotyping errors will be more transparent through precedence of Mendelian inheritance. 
Nevertheless, low-coverage WGS has been demonstrated as being effective for detecting 
rare variants influencing complex diseases (Holm et al. 2011). 
7.1.3 Smaller sample sizes 
The advent of sequencing approaches for the identification of rare variants has placed a 
limit on the number of samples that can be analysed using current technologies, due to 
available resources. As such, study designs that required smaller sample sizes have been 
favoured (Cirulli et al. 2010; Zeggini 2011). These include extreme trait design, isolated 
populations and cohorts of families (Cirulli et al. 2010; Zeggini 2011). Isolated populations 
and family studies offer not only increased allele frequencies of rare or even private  
variants, but also the potential for reduced phenotypic, environmental and genetic 
heterogeneity (Cirulli et al. 2010; Zeggini 2011). 
7.1.4 Successful application of sequencing approaches 
The 1000 Genomes Project uses WGS, exome sequencing and low-coverage WGS to catalog 
95% of variants with frequency >1% and coding variants with frequencies as low as 0.1% 
(Durbin et al. 2010). An exciting recent publication by Holm et al (Holm et al. 2011) shows 
successful application of this dataset and imputation for a project studying the complex 
cardiac disorder sick sinus syndrome in the isolated Icelandic cohort. They identified a rare 
variant (MAF 0.004) in MYH6 that was strongly associated with disease (OR 12.5). The 
success of Holm et al (Holm et al. 2011) can be in part attributed to their isolated population 
study design and its reduced genetic heterogeneity. The variant described by Holm et al 
may not be present in other populations (Zeggini 2011), limiting its utility in variant specific 
tests of prediction. This is consistent with the low-coverage 1000 Genomes pilot that 
highlighted the potential for rare variants to be ethnically unique with most of the ~9 
million new SNPs discovered being population specific (Via et al. 2010) with non-
synonymous variants more susceptible to this trend than synonymous SNPs (2010). Gene 
centric as opposed to variant centric measurements may be necessary to allow utility of risk 
assessments across diverse population groups. 
7.1.5 Modern linkage analysis 
A recent study of plasma levels of the adipocytokine adiponectin levels (Bowden et al. 2010) 
illustrated the usefulness of reliance on linkage analysis for finding families enriched with 
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large effect variants. A key finding from this paper was that only a few families may 
contribute significantly to the originally observed linkage signal (Bowden et al. 2010). These 
families were examined with exome and direct sequencing to determine the causal variant 
for adiponectin levels, and a rare variant (MAF 0.011) identified that explained 17% of the 
phenotypic variation in the whole sample, and 63% in carrier families. Association methods 
enabled detection of this variant in other families. This success validates Blangero’s 
argument that linkage analysis was unjustly discarded as a method for dissecting complex 
disease development (Blangero 2004), and that a combination of both sequencing and family 
linkage data will be an efficient method for the study of rare variants in common complex 
disease (Bowden et al. 2010; Cirulli et al. 2010).  
8. Conclusion 
The era of GWA studies has taught us a much about the influence of common variants on 
complex diseases, and revealed the influence of many previously unknown loci. As the 
disease mediating genes are in turn identified, it is anticipated that novel insights into the 
molecular pathways affecting disease risk will arise. However it has become clear that the 
contribution of common variants to common complex diseases has been overestimated, as 
substantial missing heritability for many complex phenotypes shows that only small 
proportion of overall phenotypic variation can be accounted for the vast majority of traits 
studied. Systems biology approaches combining large scale genetic and transcriptomic 
datasets appear key to the identification of the disease genes and the dearth of such well 
characterised large cohorts has no doubt contributed to the slow pace of translation.  
The study of complex diseases field now looks towards rare variants and emerging next-
generation sequencing technology for the next major steps forward, with family-based 
approaches carrying several advantages over competing designs. Until WGS becomes 
economically viable, affordable alternative approaches will provide the platform for 
advancement including exome targeted sequencing and imputation. In due course, it is 
anticipated that technological advances such as those under development by Pacific 
Biosciences will evolve to enable WGS for large sample sizes at high statistical power, 
allowing comprehensive characterisation of human genetic variation.  
Although drug focused outcomes of genetic studies are in their infancy, there is excitement 
for future success (Hirschhorn 2009; Manolio et al. 2009; Cirulli et al. 2010). It is acceptable to 
have a proportion of heritability unexplained if the variants found can initiate development 
of an effective, low cost drug (Manolio et al. 2009), therefore a variant’s usefulness might be 
based on a cost benefit ratio for treatment advancement rather than the proportion of 
heritability explained. For now the future of genetic analysis of complex disease looks bright 
as new technologies will allow great insights into the genome that were inconceivable just a 
decade ago.  
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